aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.15372/ATER20190408ateroskleroz-368Research ArticleОБЗОРЫREVIEWSБиохимические маркеры кальцификации атеросклеротических бляшекBiochemical markers of atherosclerotic plaque calcificationМаслацовН. А.MaslatsovN. A.

Маслацов Николай Анатольевич – клинический ординатор

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

maslatsoff@mail.ruРагиноЮ. И.RaginoYu. I.

Юлия Игоревна – д-р мед. наук, проф., врио руководителя

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

ragino@mail.ruНИИ терапии и профилактической медицины – филиал ФГБУ ФИЦ Институт цитологии и генетики СО РАНResearch Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS2019250420201547884Copyright © Маслацов Н.А., Рагино Ю.И., 20202020Маслацов Н.А., Рагино Ю.И.Maslatsov N.A., Ragino Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/368

В литературном обзоре освещены результаты зарубежных и российских исследований последних лет, посвященных изучению биохимических факторов и потенциальных биомаркеров кальцификации сосудистой стенки, а также атеросклеротических бляшек коронарных и сонных артерий. Результаты проведенных исследований позволяют уточнять и дополнять известные механизмы кальцификации сосудистой стенки. На сегодняшний день наиболее изучены четыре основных биомаркера сосудистой кальцификации – остеопротегерин, остеопонтин, остеонектин и остеокальцин. Таким образом, целью данного обзора явилось систематизирование современных знаний о вкладе вышеперечисленных биохимических маркеров в процессы кальцификации атеросклеротических бляшек, а также выявление потенциальных трендов в использовании данных биомаркеров в современной клинической практике.

The literature review highlights the results of foreign and Russian studies of recent years, devoted to the study of biochemical factors and potential biomarkers of calcification of the vascular wall, as well as atherosclerotic plaques of the coronary and carotid arteries. The results of the studies allow to clarify and to supplement the known mechanisms of calcification of the vascular wall. To date, the four most studied biomarkers of vascular calcification are most studied osteoprotegerin, osteopontin, osteonectin and osteocalcin.

кальцификация артерийатеросклеротическая бляшкапотенциальные биомаркерыостеопротегериностеопонтиностеонектиностеокальцинarterial calcificationatherosclerotic plaquepotential biomarkersosteoprotegerinosteopontinosteonectinosteocalcinЛитературный обзор выполнен в рамках бюджетной НИР по Государственному заданию № 0324-2018-0001 и по гранту РФФИ № 19-015-00055а «Роль сосудистого кальциноза в стабильности и нестабильности атеросклеротических бляшек».ReferencesGross M.L., Meyer H.P., Ziebart H. et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and X-ray analysis in renal and nonrenal patients // Clin. J. Am. Soc. Nephrol. 2007. Vol. 2, N 1. P. 121–134.Gross M.L., Meyer H.P., Ziebart H. et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and X-ray analysis in renal and nonrenal patients // Clin. J. Am. Soc. Nephrol. 2007. Vol. 2, N 1. P. 121–134.Kurabayashi M. Bone and calcium update; diagnosis and therapy of bone metabolism disease update. Calcification of atherosclerotic plaques: mechanism and clinical significance // Clin. Calcium. 2011. Vol. 21, N 12. P. 43–50. doi: CliCa111217931800Kurabayashi M. Bone and calcium update; diagnosis and therapy of bone metabolism disease update. Calcification of atherosclerotic plaques: mechanism and clinical significance // Clin. Calcium. 2011. Vol. 21, N 12. P. 43–50. doi: CliCa111217931800Bäck M., Aranyi T., Cancela M.L. et al. Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST action EuroSoftCalcNet // Front. Cardiovasc. Med. 2019. Vol. 18, N 5. P. 196–201. doi: 10.3389/fcvm.2018.00196Bäck M., Aranyi T., Cancela M.L. et al. Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST action EuroSoftCalcNet // Front. Cardiovasc. Med. 2019. Vol. 18, N 5. P. 196–201. doi: 10.3389/fcvm.2018.00196Di Bartolo B.A., Cartland S.P., Harith H.H. et al. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL // PLoS One. 2013. Vol. 8, N 9. P. e74211. doi: 10.1371/journal.pone.0074211Di Bartolo B.A., Cartland S.P., Harith H.H. et al. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL // PLoS One. 2013. Vol. 8, N 9. P. e74211. doi: 10.1371/journal.pone.0074211Ikeda K., Souma Y., Akakabe Y. et al. Macrophages play a unique role in the plaque calcification by enhancing the osteogenic signals exerted by vascular smooth muscle cells // Biochem. Biophys. Res. Commun. 2012. Vol. 425, N 1. P. 39–44. doi: 10.1016/j.bbrc.2012.07.045Ikeda K., Souma Y., Akakabe Y. et al. Macrophages play a unique role in the plaque calcification by enhancing the osteogenic signals exerted by vascular smooth muscle cells // Biochem. Biophys. Res. Commun. 2012. Vol. 425, N 1. P. 39–44. doi: 10.1016/j.bbrc.2012.07.045Kurabayashi M. Vascular calcification pathological mechanism and clinical application role of vascular smooth muscle cells in vascular calcification // Clin. Calcium. 2015. Vol. 25, N 5. P. 661–669. doi: CliCa1505661669Kurabayashi M. Vascular calcification pathological mechanism and clinical application role of vascular smooth muscle cells in vascular calcification // Clin. Calcium. 2015. Vol. 25, N 5. P. 661–669. doi: CliCa1505661669Sugiyama T., Yamamoto E., Fracassi F. et al. Calcified plaques in patients with acute coronary syndromes // JACC Cardiovasc. Interv. 2019. Vol. 12, N 6. P. 531–540. doi: 10.1016/j.jcin.2018.12.013Sugiyama T., Yamamoto E., Fracassi F. et al. Calcified plaques in patients with acute coronary syndromes // JACC Cardiovasc. Interv. 2019. Vol. 12, N 6. P. 531–540. doi: 10.1016/j.jcin.2018.12.013Davaine J.M., Quillard T., Brion R. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability // PLoS One. 2014. Vol. 9, N 9. ID e107642. doi: 10.1371/journal.pone.0107642Davaine J.M., Quillard T., Brion R. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability // PLoS One. 2014. Vol. 9, N 9. ID e107642. doi: 10.1371/journal.pone.0107642Allison M.A., Hsi S., Wassel C.L. et al. Calcified atherosclerosis in different vascular beds and the risk of mortality // Arterioscler. Thromb. Vasc. Biol. 2012. Vol. 32, N 1. P. 140–146. doi: 10.1161/ATVBAHA.111.235234Allison M.A., Hsi S., Wassel C.L. et al. Calcified atherosclerosis in different vascular beds and the risk of mortality // Arterioscler. Thromb. Vasc. Biol. 2012. Vol. 32, N 1. P. 140–146. doi: 10.1161/ATVBAHA.111.235234Pesaro A.E., Katz M., Liberman M. et al. Circulating osteogenic proteins are associated with coronary artery calcification and increase after myocardial infarction // PLoS One. 2018. Vol. 13, N 8. ID e0202738. doi: 10.1371/journal.pone.0202738Pesaro A.E., Katz M., Liberman M. et al. Circulating osteogenic proteins are associated with coronary artery calcification and increase after myocardial infarction // PLoS One. 2018. Vol. 13, N 8. ID e0202738. doi: 10.1371/journal.pone.0202738Quercioli A., Luciano Viviani G., Dallegri F., Mach F., Montecucco F. Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification // Crit. Pathw. Cardiol. 2010. Vol. 9, N 4. P. 227–230. doi: 10.1097/HPC.0b013e318200ec27Quercioli A., Luciano Viviani G., Dallegri F., Mach F., Montecucco F. Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification // Crit. Pathw. Cardiol. 2010. Vol. 9, N 4. P. 227–230. doi: 10.1097/HPC.0b013e318200ec27Ostric M., Kukuljan M., Markić D. et al. Expression of bone-related proteins in vascular calcification and its serum correlations with coronary artery calcification score // J. Biol. Regul. Homeost. Agents. 2019. Vol. 33, N 1. P. 29–38.Ostric M., Kukuljan M., Markić D. et al. Expression of bone-related proteins in vascular calcification and its serum correlations with coronary artery calcification score // J. Biol. Regul. Homeost. Agents. 2019. Vol. 33, N 1. P. 29–38.Вербовой А.Ф., Цанава И.А., Митрошина Е.В., Шаронова Л.А. Остеопротегерин – новый маркер сердечно-сосудистых заболеваний // Терапевт. арх. 2017. Т. 89, № 4. С. 91–94. doi: 10.17116/terarkh201789491-94Вербовой А.Ф., Цанава И.А., Митрошина Е.В., Шаронова Л.А. Остеопротегерин – новый маркер сердечно-сосудистых заболеваний // Терапевт. арх. 2017. Т. 89, № 4. С. 91–94. doi: 10.17116/terarkh201789491-94Rattazzi M., Faggin E., Bertacco E. et al. RANKL expression is increased in circulating mononuclear cells of patients with calcific aortic stenosis // J. Cardiovasc. Transl. Res. 2018. Vol. 11, N 4. P. 329–338. doi: 10.1007/s12265-018-9804-2Rattazzi M., Faggin E., Bertacco E. et al. RANKL expression is increased in circulating mononuclear cells of patients with calcific aortic stenosis // J. Cardiovasc. Transl. Res. 2018. Vol. 11, N 4. P. 329–338. doi: 10.1007/s12265-018-9804-2Mohammadpour A.H., Shamsara J., Nazemi S. et al. Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: A pilot study // Thrombosis. 2012. Vol. 12. ID 306263. doi: 10.1155/2012/306263Mohammadpour A.H., Shamsara J., Nazemi S. et al. Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: A pilot study // Thrombosis. 2012. Vol. 12. ID 306263. doi: 10.1155/2012/306263Quercioli A., Montecucco F., Bertolotto M. et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling // Eur. J. Clin. Invest. 2010. Vol. 40, N 7. P. 645–654. doi: 10.1111/j.13652362.2010.02308.xQuercioli A., Montecucco F., Bertolotto M. et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling // Eur. J. Clin. Invest. 2010. Vol. 40, N 7. P. 645–654. doi: 10.1111/j.13652362.2010.02308.xRochette L., Meloux A., Rigal E. et al. The role of osteoprotegerin in vascular calcification and bone metabolism: The basis for developing new therapeutics // Calcif. Tissue Int. 2019. Vol. 105, N 3. P. 239–251. doi: 10.1007/s00223-019-00573-6Rochette L., Meloux A., Rigal E. et al. The role of osteoprotegerin in vascular calcification and bone metabolism: The basis for developing new therapeutics // Calcif. Tissue Int. 2019. Vol. 105, N 3. P. 239–251. doi: 10.1007/s00223-019-00573-6Panizo S., Cardus A., Encinas M. et al. RANKL increases vascular smooth muscle cell calcification through a RANKLBMP4-dependent pathway // Circ. Res. 2009. Vol. 104, N 9. P. 1041–1048. doi: 10.1161/CIRCRESAHA.108.189001Panizo S., Cardus A., Encinas M. et al. RANKL increases vascular smooth muscle cell calcification through a RANKLBMP4-dependent pathway // Circ. Res. 2009. Vol. 104, N 9. P. 1041–1048. doi: 10.1161/CIRCRESAHA.108.189001Krzanowski M., Krzanowska K., Dumnicka P. et al. Elevated circulating osteoprotegerin levels in the plasma of hemodialyzed patients with severe artery calcification // Ther. Apher. Dial. 2018. Vol. 22, N 5. P. 519–529. doi: 10.1111/1744-9987.12681Krzanowski M., Krzanowska K., Dumnicka P. et al. Elevated circulating osteoprotegerin levels in the plasma of hemodialyzed patients with severe artery calcification // Ther. Apher. Dial. 2018. Vol. 22, N 5. P. 519–529. doi: 10.1111/1744-9987.12681Ahmed S., Sobh R. Predictive value of osteoprotegerin for early detection coronary artery calcification in type 2 diabetes mellitus patients in correlation with extent of calcification detected by multidetector computed tomography // Endocr. Metab. Immune Disord. Drug Targets. 2019. Vol. 11. P. 256–263. doi: 10.2174/1871530319666190211122858Ahmed S., Sobh R. Predictive value of osteoprotegerin for early detection coronary artery calcification in type 2 diabetes mellitus patients in correlation with extent of calcification detected by multidetector computed tomography // Endocr. Metab. Immune Disord. Drug Targets. 2019. Vol. 11. P. 256–263. doi: 10.2174/1871530319666190211122858Kwon A., Choi Y.S., Choi Y.W. et al. Serum osteoprotegerin is associated with calcified carotid plaque: a Strobe-Compliant Observational Study // Medicine. 2016. Vol. 95, N 15. ID e3381. doi: 10.1097/MD.0000000000003381Kwon A., Choi Y.S., Choi Y.W. et al. Serum osteoprotegerin is associated with calcified carotid plaque: a Strobe-Compliant Observational Study // Medicine. 2016. Vol. 95, N 15. ID e3381. doi: 10.1097/MD.0000000000003381Perez de Ciriza C., Moreno M., Restituto P. et al. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification // Clin. Biochem. 2014. Vol. 47, N 18. P. 272–278. doi: 10.1016/j.clinbiochem.2014.09.004Perez de Ciriza C., Moreno M., Restituto P. et al. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification // Clin. Biochem. 2014. Vol. 47, N 18. P. 272–278. doi: 10.1016/j.clinbiochem.2014.09.004Heymann M.F., Herisson F., Davaine J.M. et al. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds // Cytokine. 2012. Vol. 58, N 2. P. 300–306. doi: 10.1016/j.cyto.2012.02.004Heymann M.F., Herisson F., Davaine J.M. et al. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds // Cytokine. 2012. Vol. 58, N 2. P. 300–306. doi: 10.1016/j.cyto.2012.02.004Icer M.A., Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin // Clin. Biochem. 2018. Vol. 59. P. 17–24. doi: 10.1016/j.clinbiochem.2018.07.003Icer M.A., Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin // Clin. Biochem. 2018. Vol. 59. P. 17–24. doi: 10.1016/j.clinbiochem.2018.07.003Lok Z.S.Y., Lyle A.N. Osteopontin in vascular disease // Arterioscler. Thromb. Vasc. Biol. 2019. Vol. 39, N 4. P. 613–622. doi: 10.1161/ATVBAHA.118.311577Lok Z.S.Y., Lyle A.N. Osteopontin in vascular disease // Arterioscler. Thromb. Vasc. Biol. 2019. Vol. 39, N 4. P. 613–622. doi: 10.1161/ATVBAHA.118.311577Li X.Y., Chen R., Zhong W. et al. CD137 signaling promotes the formation of plaque calcification via inhibiting the fusion of autophagy and lysosomal in Apo E(-/-) mice // Zhonghua Xin Xue Guan Bing ZaZhi. 2017. Vol. 45, N 12. P. 1078–1085. doi: 10.3760/cma.j.issn.0253-3758.2017.12.013Li X.Y., Chen R., Zhong W. et al. CD137 signaling promotes the formation of plaque calcification via inhibiting the fusion of autophagy and lysosomal in Apo E(-/-) mice // Zhonghua Xin Xue Guan Bing ZaZhi. 2017. Vol. 45, N 12. P. 1078–1085. doi: 10.3760/cma.j.issn.0253-3758.2017.12.013Higgins C.L., Isbilir S., Basto P. et al. Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcifiedhuman carotid atheroma // Protein J. 2015. Vol. 34, N 5. P. 315–328. doi: 10.1007/s10930-015-9620-3Higgins C.L., Isbilir S., Basto P. et al. Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcifiedhuman carotid atheroma // Protein J. 2015. Vol. 34, N 5. P. 315–328. doi: 10.1007/s10930-015-9620-3Polonskaya Y.V., Kashtanova E.V., Murashov I.S. et al. Associations of osteocalcin, osteoprotegerin, and calcitonin with inflammation biomarkers in atherosclerotic plaques of coronary arteries // Bull. Exp. Biol. Med. 2017. Vol. 162, N 6. P. 726–729. doi: 10.1007/s10517-017-3698-xPolonskaya Y.V., Kashtanova E.V., Murashov I.S. et al. Associations of osteocalcin, osteoprotegerin, and calcitonin with inflammation biomarkers in atherosclerotic plaques of coronary arteries // Bull. Exp. Biol. Med. 2017. Vol. 162, N 6. P. 726–729. doi: 10.1007/s10517-017-3698-xIkeda T., Shirasawa T., Esaki Y. et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta // J. Clin. Invest. 1993. Vol. 92, N 6. P. 2814–2820.Ikeda T., Shirasawa T., Esaki Y. et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta // J. Clin. Invest. 1993. Vol. 92, N 6. P. 2814–2820.Dolzhenko A., Richter T., Sagalovsky S. Vascular calcification, atherosclerosis and bone loss (osteoporosis): new pathophysiological mechanisms and future perspectives for pharmacological therapy // Альм. клин. мед. 2016. Т. 44, № 4. С. 513–534.Dolzhenko A., Richter T., Sagalovsky S. Vascular calcification, atherosclerosis and bone loss (osteoporosis): new pathophysiological mechanisms and future perspectives for pharmacological therapy // Альм. клин. мед. 2016. Т. 44, № 4. С. 513–534.Zwakenberg S.R., van der Schouw Y.T., Schalkwijk C.G., Spijkerman A.M.W., Beulens J.W.J. Bone markers and cardiovascular risk in type 2 diabetes patients // Cardiovasc. Diabetol. 2018. Vol. 17, N 1. P. 45. doi: 10.1186/s12933-018-0691-2Zwakenberg S.R., van der Schouw Y.T., Schalkwijk C.G., Spijkerman A.M.W., Beulens J.W.J. Bone markers and cardiovascular risk in type 2 diabetes patients // Cardiovasc. Diabetol. 2018. Vol. 17, N 1. P. 45. doi: 10.1186/s12933-018-0691-2Zhang M., Sara J.D., Wang F.L. et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients // Cardiovasc. Diabetol. 2015. Vol. 14. ID 64. doi: 10.1186/s12933-015-0214-3Zhang M., Sara J.D., Wang F.L. et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients // Cardiovasc. Diabetol. 2015. Vol. 14. ID 64. doi: 10.1186/s12933-015-0214-3Jeremias Z., Rat N., Benedek I. et al. High iliac calcium score is associated with increased severity and complexity of peripheral arterial disease and predicts global atherosclerotic burden // Vasa. 2018. Vol. 47, N 5. P. 377–386. doi: 10.1024/0301-1526/a000718Jeremias Z., Rat N., Benedek I. et al. High iliac calcium score is associated with increased severity and complexity of peripheral arterial disease and predicts global atherosclerotic burden // Vasa. 2018. Vol. 47, N 5. P. 377–386. doi: 10.1024/0301-1526/a000718Rosset E.M., Bradshaw A.D. SPARC/osteonectin in mineralized tissue // Matrix Biol. 2016. Vol. 52-54. P. 78–87. doi: 10.1016/j.matbio.2016.02.001Rosset E.M., Bradshaw A.D. SPARC/osteonectin in mineralized tissue // Matrix Biol. 2016. Vol. 52-54. P. 78–87. doi: 10.1016/j.matbio.2016.02.001Вербовой А.Ф., Митрошина Е.В., Пашенцева А.В. Взаимосвязь патогенеза атеросклероза и остеопороза // Ожирение и метаболизм. 2016. Т. 13, № 4. С. 8–14. doi: 10.14341/OMET201648-14Вербовой А.Ф., Митрошина Е.В., Пашенцева А.В. Взаимосвязь патогенеза атеросклероза и остеопороза // Ожирение и метаболизм. 2016. Т. 13, № 4. С. 8–14. doi: 10.14341/OMET201648-14García-Gómez M.C., Vilahur G. Osteoporosis and vascular calcification: A shared scenario // Clin. Investig. Arterioscler. 2019. Vol. 6. ID S0214. doi: 10.1016/j.arteri.2019.03.008García-Gómez M.C., Vilahur G. Osteoporosis and vascular calcification: A shared scenario // Clin. Investig. Arterioscler. 2019. Vol. 6. ID S0214. doi: 10.1016/j.arteri.2019.03.008Ciceri P., Elli F., Cappelletti L. Osteonectin (SPARC) expression in vascular calcification: in vitro and ex vivo studies // Calcif. Tissue Int. 2016. Vol. 99, N 5. P. 472–480.Ciceri P., Elli F., Cappelletti L. Osteonectin (SPARC) expression in vascular calcification: in vitro and ex vivo studies // Calcif. Tissue Int. 2016. Vol. 99, N 5. P. 472–480.Рагино Ю.И., Каштанова Е.В., Чернявский А.М., Волков А.М., Полонская Я.В., Иванова М.В. Связь остеонектина с некоторыми биомаркерами при стенозирующем атеросклерозе и кальцинозе коронарных артерий // Рос. кардиол. журн. 2010. № 4. С. 20–24.Рагино Ю.И., Каштанова Е.В., Чернявский А.М., Волков А.М., Полонская Я.В., Иванова М.В. Связь остеонектина с некоторыми биомаркерами при стенозирующем атеросклерозе и кальцинозе коронарных артерий // Рос. кардиол. журн. 2010. № 4. С. 20–24.Рагино Ю.И., Каштанова Е.В., Чернявский А.М., Полонская Я.В., Воевода М.И. Связь остеонектина с воспалительными, окислительными и липидными биомаркерами при коронарном атеросклерозе и его осложнениях // Атеросклероз и дислипидемии. Рос. кардиол. журн. 2014. № 4. С. 20–25.Рагино Ю.И., Каштанова Е.В., Чернявский А.М., Полонская Я.В., Воевода М.И. Связь остеонектина с воспалительными, окислительными и липидными биомаркерами при коронарном атеросклерозе и его осложнениях // Атеросклероз и дислипидемии. Рос. кардиол. журн. 2014. № 4. С. 20–25.дрыгина Л.Б., Корсакова Н.Е. Роль белков костного матрикса в регуляции сосудистой кальцификации // Клин.-лаб. консилиум. 2009. № 5. С. 14–20.дрыгина Л.Б., Корсакова Н.Е. Роль белков костного матрикса в регуляции сосудистой кальцификации // Клин.-лаб. консилиум. 2009. № 5. С. 14–20.Evrard S., Delanaye P., Kamel S. et al. Vascular calcification: from pathophysiology to biomarkers // Clin. Chim. Acta. 2015. 438. P. 401–414. doi: 10.1016/j.cca.2014.08.034Evrard S., Delanaye P., Kamel S. et al. Vascular calcification: from pathophysiology to biomarkers // Clin. Chim. Acta. 2015. 438. P. 401–414. doi: 10.1016/j.cca.2014.08.034Akers E.J., Nicholls S.J., Di Bartolo B. A plaque calcification // Arterioscler. Thromb. Vasc. Biol. 2019. Vol. 29. P. 119–125. doi: 10.1161/ATVBAHA.119.311574Akers E.J., Nicholls S.J., Di Bartolo B. A plaque calcification // Arterioscler. Thromb. Vasc. Biol. 2019. Vol. 29. P. 119–125. doi: 10.1161/ATVBAHA.119.311574Emoto M., Mori K., Lee E. et al. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus // Metabolism. 2010. Vol. 59, N 6. P. 873–878. doi: 10.1016/j.metabol.2009.10.005Emoto M., Mori K., Lee E. et al. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus // Metabolism. 2010. Vol. 59, N 6. P. 873–878. doi: 10.1016/j.metabol.2009.10.005Seidu S., Kunutsor S.K., Khunti K. Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis // Scand. Cardiovasc. J. 2019. Vol. 22. P. 1–10. doi: 10.1080/14017431.2019.1655166Seidu S., Kunutsor S.K., Khunti K. Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis // Scand. Cardiovasc. J. 2019. Vol. 22. P. 1–10. doi: 10.1080/14017431.2019.1655166Zhang H., Wang L.J., Si D.L. et al. Correlation between osteocalcin-positive endothelial progenitor cells and spotty calcification in patients with coronary artery disease // Clin. Exp. Pharmacol. Physiol. 2015. Vol. 42, N 7. P. 734–739. doi: 10.1111/1440-1681.12366Zhang H., Wang L.J., Si D.L. et al. Correlation between osteocalcin-positive endothelial progenitor cells and spotty calcification in patients with coronary artery disease // Clin. Exp. Pharmacol. Physiol. 2015. Vol. 42, N 7. P. 734–739. doi: 10.1111/1440-1681.12366Foresta C., Strapazzon G., De Toni L. et al. Platelets express and release osteocalcin and co-localize in human calcified atherosclerotic plaques // J. Thromb. Haemost. 2013. Vol. 11, N 2. P. 357–365. doi: 10.1111/jth.12088Foresta C., Strapazzon G., De Toni L. et al. Platelets express and release osteocalcin and co-localize in human calcified atherosclerotic plaques // J. Thromb. Haemost. 2013. Vol. 11, N 2. P. 357–365. doi: 10.1111/jth.12088

The authors declare that there are no conflicts of interest present.